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Abstract
Introduction: Microthrombosis is often observed in lupus nephritis (LN) lesions, but its clinical significance is
unknown. We evaluated the clinicopathologic correlations of renal microthrombosis and inflammatory markers in
LN.
Methods: Kidney biopsies from 58 patients with systemic lupus erythematosus (SLE) proliferative nephritis were
analyzed with immunohistochemistry (IHC) for intravascular platelet aggregates (CD61), macrophagic infiltration
(CD68), and activated complement deposition (C4d). Clinical data at the time of kidney biopsy and follow-up were
analyzed with regard to pathologic IHC data.
Results: Microthrombosis was present in 52% of the tissues. It was significantly more prevalent in patients with
antiphospholipid antibodies (aPLs) (62% versus 42%). The presence of microthrombosis significantly correlated with
higher macrophagic infiltration. Macrophagic infiltration but not microthrombosis was significantly correlated with
C4d deposition. Only macrophagic infiltration showed a correlation with SLE and renal activity (proteinuria and
active sediment), whereas neither the presence of CD61+ microthrombi nor the extent of C4d deposition
correlated with LN severity or outcome.
Conclusions: Microthrombosis is associated with higher macrophagic infiltration in LN but does not seem to
increase independently the severity of renal damage. Macrophagic infiltration was the best marker of SLE and renal
activity in this LN series.
Introduction
Lupus nephritis (LN) develops in 30% to 50% of patients
with systemic lupus erythematosus (SLE) [1]. Standard
clinical practice is to perform a renal biopsy if clinical or
analytic parameters suggest renal involvement. Although
some clinical variables, such as elevation of serum creati-
nine or persistent elevations of blood pressure, have
prognostic value, histologic information obtained from
biopsies continues to be indispensable for classification
and outcome prediction [2,3]. Among local inflammatory
markers, glomerular and interstitial macrophage accumu-
lation is a feature of the most aggressive forms of human
glomerulonephritis [4]. These cells, together with dendri-
tic cells, are the major source of inflammatory cytokines
[5], and their interaction with resident T cells may
amplify renal inflammation. Monocyte numbers in the
urine and urinary levels of the monocyte chemoattractant
protein-1 (MCP-1) have been found to be useful markers
to monitor the activity of LN [6,7]. In patients with pro-
liferative forms of LN, MCP-1 also may play a role in
modulating interstitial inflammatory cell infiltration and
tubulointerstitial damage via the transforming growth
factor (TGF)-beta 1 pathway [8]. Therefore, glomerular
and tubular macrophagic infiltration has important
pathogenetic implications, and it is one of the individual
variables that best correlates with clinical parameters [9].
Vascular occlusions can be observed in LN and may
relate to worse renal outcomes [10]. Acute thrombosis
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or chronic occlusive lesions in glomeruli and/or renal
arterioles have also been described in patients with anti-
phospholipid syndrome (APS) [11,12]. Acute thrombosis
in LN, as detected with routine histology, is rarely
observed, possibly because of its relatively sparse pre-
sence and the small size of tissue samples obtained with
renal biopsy. Other chronic, nonspecific vascular occlu-
sive histologic lesions may relate to older age and cardi-
ovascular risk factors associated with arteriosclerotic
disease, even in patients without aPLs (antiphospholipid
antibodies) [13]. This type of chronic occlusive vascular
lesions has been associated with a worse renal-function
outcome. Immunohistochemical detection of CD61+
intravascular platelets in SLE renal biopsies increases
the sensitivity to detect microthrombosis and reveals a
high prevalence of microthrombotic lesions in either
aPL-negative or -positive LN patients [13]. Whether
microthrombotic lesions are a consequence of renal
inflammation or independently contribute to renal
damage is unclear [10-12].
A link between activation of the complement system
and aPL-induced thrombosis has been described in mur-
ine APS models [14,15]. In SLE patients with thrombosis
and vascular aPL-related pathology, increased C4d deposi-
tion on platelets has been reported [16]. In SLE patients
without aPL, C4d kidney deposition also correlates with
thrombosis [17]. Therefore, complement activation might
be a common mechanism of renal inflammation and
thrombosis in patients with LN with or without aPL.
We undertook this study to investigate the potential
relation between local complement activation, macropha-
gic infiltration, and renal microthrombosis, as well as
their potential independent contribution to renal damage
in a large series of SLE patients with proliferative nephri-
tis. Our data provide evidence of the relation between
these three processes but do not support an independent
contribution of microthrombosis to renal damage.
Materials and methods
Patients and kidney biopsies
From a large cohort of SLE patients followed up at two
University Hospitals between 1986 and 2010, we selected
those with available kidney biopsy specimens to perform
histologic and immunohistochemical studies. All patients
fulfilled at least four of the American College of Rheuma-
tology criteria for the diagnosis of SLE [18]. The study
received approval by the Ethics Committee of Hospital
12 de Octubre. This study was performed on previously
collected and filed pathology materials obtained after
informed patient consent. Kidney biopsies had been
performed for diagnostic purposes in patients with protei-
nuria higher than 500 mg/day, abnormal urinary sediment,
or elevated serum creatinine level. We considered that
clinicopathologic correlations could be independently ana-
lyzed in different episodes, and therefore, biopsies from
different episodes of the same patient were included when
available. Kidney histology was evaluated and classified
according to the ISN/RPS classification [19] by a patholo-
gist who was blinded to patients’ clinical and IHC data.
Hematoxylin-eosin and phosphotungstic acid-hematoxylin
(PAS) stained sections were evaluated. The whole series
included 86 patients. In total, 101 histologic samples were
analyzed. Among them, we selected 65 (64%) samples with
proliferative nephritis (ISN/RPS types II, III, and IV) from
58 patients for further study. Their demographic, clinical,
laboratory, and pathology characteristics before and at
renal biopsy are detailed in Table 1.
APS was diagnosed according to the Sapporo criteria
[20]. Definite APS was considered if at least one of the fol-
lowing clinical and laboratory criteria was satisfied. Clini-
cal criteria included the presence of either vascular
thrombosis or pregnancy morbidity. Laboratory criteria
included the presence of aPL on two or more occasions at
least 6 weeks apart, as demonstrated by one or more of
the following: IgG and/or IgM anticardiolipin (aCL) anti-
bodies in moderate or high titer and lupus anticoagulant
(LA) activity. LA was detected after updated guidelines of
the Subcommittee for the Standardization of Lupus Antic-
oagulant of the International Society of Thrombosis and
Haemostasis [21], whereas aCLs were detected with
enzyme-linked immunosorbent assay (ELISA) by following
the manufacturer’s instructions (Quanta Lite ACA IgG III
and IgM III; Inova Diagnostics Inc, San Diego, CA, USA).
The following demographic data were recorded: sex, age,
age at SLE diagnosis, age at renal disease, and time from
kidney biopsy to the end of follow-up. Clinical and labora-
tory SLE data, including the disease-activity index SLEDAI
[22], cardiovascular risk factors (high blood pressure
(HBP), diabetes, hypercholesterolemia and/or hypertrigly-
ceridemia, smoking, and hormonal contraception), APS
criteria, and previous therapy were recorded.
Renal manifestations at biopsy and during the follow-
up, specific therapy, response and time to response, and
relapse and time to relapse were analyzed. Renal mani-
festations included HBP, renal failure defined as serum
creatinine ≥1.5 mg/dl and/or creatinine clearance ≤65
ml/min, 24-hour proteinuria, hematuria, leukocyturia,
and cellular casts. Complete clinical response to therapy
was defined by 24 hours of proteinuria lower than 500
mg, normal urine sediment, and normal renal function
(serum creatinine, < 1.5 mg/dl, and creatinine clearance,
> 75 ml/min). Partial response to treatment was defined
by improvement in all these parameters not reaching
complete-response criteria. The presence of aPL (LA,
IgG, or IgM aCL) and APS criteria before and after kid-
ney disease was also recorded.
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Immunohistochemical detection of CD61-positive platelet
microthrombi, CD68-positive macrophages, and activated
complement factor C4d
Immunohistochemical studies were performed on paraf-
fin-embedded kidney sections. Immunostaining with
either monoclonal mouse anti-human CD68 (CD68,
clone KP1; DakoCytomation Denmark A/S, Glostrup,
Denmark), monoclonal mouse anti-human gpIIIa
(CD61, sz21; Immunotech, Marseille, France), or poly-
clonal rabbit anti-human C4d (C4dpAb; Biomedica
Medizinprodukte GmbH & Co KG, Vienna, Austria)
were performed. Renal sections from patients with pri-
mary thrombotic microangiopathy (TMA) were used as
positive controls for CD61. Renal sections from a nor-
mal kidney were used as negative controls.
Sections were deparaffinized and pretreated with 10
μg/ml proteinase K (P6556; Sigma-Aldrich Quimica SA,
Madrid, Spain) in the case of CD61 detection, or boiled
in 1 mM EDTA or citrate buffer 10 mM, pH 6, for
CD68 and C4d detection, respectively. The slides were
incubated overnight at 4°C with primary antibodies.
Immunohistochemical staining was performed with a
peroxidase avidin-biotin complex technique (SK-4100;
Vector Laboratories Inc., Burlingame, CA, USA). Diami-
nobenzidine was used as chromogen substrate, and sec-
tions were counterstained with hematoxylin.
Glomerular and extraglomerular CD68 and C4d stain-
ing was quantified by using the public domain image-
processing program, Image J software [23]. In brief, the
percentage of stained area in 10 glomeruli and 10 extra-
glomerular areas randomly selected from each sample
was calculated. Two blinded and independent observers
analyzed all slides.
Statistical analysis
The associations between categoric variables were tested
by using the c2 or Fisher Exact test, where appropriate.
The odds ratios (ORs) with the corresponding 95% con-
fidence intervals (95% CIs) were calculated. For continu-
ous variables, the comparisons were carried out by using
the t test for two independent samples. A Spearman
rank correlation was used to detect correlations among
different study parameters. P values less than 0.05 were
considered significant. The analysis was performed by
using advanced SPSS software version 15.
Results
Histologic and IHC detection of microthrombotic lesions,
macrophagic infiltration, and C4d deposition in kidney
biopsies
In healthy, histologically normal kidney sections used as
controls for IHC, CD61-positive platelet aggregates were
not detected (Figure 1a). CD61-positive microthrombi
were detected in 52% of the proliferative LN tissues
Table 1 Demographic, clinical, and laboratory
characteristics of SLE patients with proliferative nephritis
Patients (n = 58)
n (% or range)
Sex: F/M 54/4 (93/7)
Mean age (years) 39 ± 12 (22-75)
Mean age at SLE diagnosis (years) 26 ± 11 (8-66)
Mean age at nephritis (years) 29 ± 12 (8-73)
Mean duration of follow-up (months) 97 (1-273)
Cardiovascular risk factors 35 (58)
Positive aPL 31 (53.4)
APS 8 (14.8)
ANA (+) 58 (100)
a-DNA (+) 49 (84.5)
a-Ro (+) 21 (42.9)
a-Sm (+) 16 (33.3)
a-RNP (+) 11 (22.9)
Low complement levels 52 (91.2)
Treatment before first renal biopsy
Antiaggregation 20/65 (31)
Oral anticoagulation 2/65 (3.1)
Glucocorticoids 50/65 (77)
≤7.5 mg/d prednisone 42%
< 7.5 to 30 mg/d
prednisone
43%
> 30 to 60 mg/d
prednisone
10%




Type II 2/65 (3)
Type III-A 13/65 (20)
Type III-A/C 4/65 (6.1)
Type III-A + V 2/65 (3)
Type IV-SA 10/65 (15.4)
Type IV-SA/C 4/65 (6.1)
Type IV-GA 23/65 (35.4)
Type IV-GA/C 5/65 (7.7)
Type IV-GA/C + V 2/65 (3)
24 hours proteinuria (mg)a 3,355.1 ± 3,372.3 (230-
19,700)
Hematuria (+)a 56 (86.2)
Leukocyturia (+)a 52 (80)
Cellular casts (+)a 42 (64.6)
Mean serum creatinine (mg/dl)a 1.1 ± 0.5 (0.4-3.4)
Mean creatinine clearance (ml/min)a 91.8 ± 44.4 (25-289)
Renal failurea 17 (26.2)
HBPa 35 (53.8)
SLEDAIa 20.4 (4-36)
Response to treatment 50 (83.3)
Mean time of response (months) 15 ± 19 (1-101)
Cardiovascular risk factors include high blood pressure (HBP), diabetes,
hypercholesterolemia and/or hypertriglyceridemia, smoking, and hormonal
contraception. aValues at renal biopsy.
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(79% in glomerular and 62% in extraglomerular vessels)
(Figure 1d, g, j).
CD68-positive macrophages were identified in the
mesangial areas of both normal (Figure 1b) and lupus
glomeruli (Figure 1e), as well as in extraglomerular
areas (Figure 1h). The density of CD68-positive macro-
phages in both glomerular and extraglomerular areas
was greatly increased in lupus patients. The mean
stained area was 2.37% ± 3.02% and 0.72% ± 0.98% in
glomerular and extraglomerular regions of lupus sec-
tions, respectively, compared with 0.0004% ± 0.0005%
and 0.0003% ± 0.0007% in normal kidney.
C4d deposition was undetectable in normal kidney
sections (Figure 1c), whereas it was detected in most
SLE biopsies, in either glomerular (78%) or extraglomer-
ular (86%) regions (Figure 1f, i). The mean C4d-stained
glomerular and extraglomerular areas were 2.76% ±
3.73% and 1.04% ± 1.32%, respectively. The main extra-
glomerular pattern was diffuse linear C4d deposition
along peritubular capillaries (98%), although some focal
arteriolar C4d staining was also found in interstitial ves-
sels (19%) (Figure 1l).
Clinical and laboratory correlations of platelet
aggregates, macrophage infiltration, and C4d deposition
Patients with glomerular CD61-positive microthrombi
had significantly higher glomerular (P = 0.03) macro-






Figure 1 Immunohistochemical detection of platelet microthrombi lesions, macrophagic infiltration, and activated complement
deposition in kidney biopsies. CD61 (left), CD68 (middle), and C4d (right) antigens were detected with immunoperoxidase (brown) in serial
sections of healthy kidney (a through c) and SLE nephritis tissues (d through l). SLE glomerular (d through f) or extraglomerular (g through i)
markers are shown. Positive CD61 microthrombi (j), CD68 infiltration (k), and C4d perivascular deposition (l) were detected. Sections were
counterstained with hematoxylin. Original magnification, ×400.
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positively correlated with extraglomerular macrophage
infiltration (r = 0.4; P = 0.004), but mean C4d deposi-
tion was similar in patients with or without CD61-posi-
tive microthrombi.
The presence of platelet aggregates was significantly
higher in patients with positive aPL (62% versus 42%;
OR, 4.4; CI, 1.5 to 12.8; P = 0.005), but it was similar in
patient groups with or without definite APS or with or
without previous cardiovascular risk factors. No correla-
tions were found between microthrombosis and SLE or
renal clinical data, including positive anti-dsDNA anti-
bodies, low complement levels, SLEDAI, 24-hour protei-
nuria, serum creatinine, creatinine clearance, or the
presence of hematuria, leukocyturia, cellular casts, HBP,
or renal failure.
Both glomerular and extraglomerular macrophagic
infiltrations positively correlated with SLE manifesta-
tions. Glomerular macrophagic infiltration correlated
with SLEDAI (r = 0.5; P < 0.001) and was significantly
higher in patients with positive anti-dsDNA antibodies
(P < 0.001) or low complement levels (P < 0.001) at
biopsy. Regarding renal manifestations, glomerular
macrophagic infiltration positively correlated with 24-
hour proteinuria (r = 0.4; P = 0.002) and was associated
with the presence of microhematuria (P < 0.001), and
cellular casts (P = 0.001). Extraglomerular macrophage
infiltration correlated with SLEDAI (r = 0.3; P = 0.01)
but was not associated with the presence of anti-dsDNA
antibodies or low complement levels. Regarding renal
manifestations, extraglomerular macrophage infiltration
correlated with 24-hour proteinuria (r = 0.4; P = 0.001)
but not with other analytic parameters. No correlation
was found between glomerular or extraglomerular
macrophage infiltration and renal function defined by
creatinine clearance at biopsy.
Extraglomerular C4d deposition was significantly
higher in patients with positive anti-dsDNA antibodies
(P = 0.01) and correlated with SLEDAI (r = 0.4; P =
0.003) and 24-hour proteinuria (r = 0.3; P = 0.03). No
differences in extraglomerular C4d deposition were
found when we considered other clinical or laboratory
parameters of renal function and SLE activity. Glomeru-
lar C4d deposition did not show any specific trend stra-
tified by all clinical and laboratory variables. Clinical and
laboratory correlations of platelet aggregates, macro-
phage infiltration, and C4d deposition are detailed in
Table 2.
As initial therapy for LN, all patients received high
doses of steroids (≥1 mg/kg/day) as well as one of the
following immunosuppressive drugs: cyclophosphamide
(79%), mycophenolate mofetil (17.7%), or azathioprine
(1.6%). In addition, 54.2% received aspirin, and 5.1%,
oral anticoagulants. Most patients (77%) had been trea-
ted with steroids before LN development for other
manifestations at variable doses (Table 1). Twenty
patients were treated with low-dose aspirin, and two
patients were taking oral anticoagulation before LN
development. In most patients treated with aspirin, indi-
cation was positive for LA and/or aCL antibodies (n =
12). Some patients received aspirin for HBP. The two
patients receiving oral anticoagulation had previous
venous or arterial thrombosis. Different groups of
patients stratified by aspirin or steroid dose did not
show any trend toward a different expression of LN or
platelet aggregates incidence, or differences in the long-
term outcomes. Fifty (83.3%) patients responded to
treatment, and the mean time to partial or complete
response was of 15.2 months (range, 1 to 101 months).
To analyze the potential long-term effect of immunohis-
tochemical findings on clinical and renal outcomes, we
selected only patients homogeneously treated with intra-
venous cyclophosphamide according to the NIH proto-
col after excluding repeated episodes of LN [24]. In
brief, induction therapy consisted of six monthly boluses
of intravenous cyclophosphamide (0.5 to 1 g per square
meter, further adjusted by leukocyte count) and gluco-
corticoids. After 6 months, patients were treated with
intravenous cyclophosphamide boluses every 3 months
and for at least 12 months after remission or stability.
Maintenance therapy was variable and, according to
clinical practice, included azathioprine, mycophenolate
mofetil, or antimalarials with glucocorticoids. Taking
into account only those patients (n = 43) who had
received the same induction treatment, we did not
found significant correlations between the presence of
CD61+ microthrombi, macrophagic infiltration, or C4d
deposition, and clinical outcomes including percentage
of response to therapy, mean time to response, percen-
tage of relapse, and long-term renal function.
Discussion
These data show that renal microthrombosis is highly
prevalent in LN, affecting half of the patients with pro-
liferative LN. It is more prevalent in patients with aPL,
consistent with previous reports [13]. Moreover, micro-
thrombosis correlates with higher macrophagic infiltra-
tion as a marker of inflammatory activity but not with
C4d deposition. However, only macrophagic infiltration
showed a correlation with SLE renal activity (proteinuria
and active sediment), and neither the presence of CD61
+ microthrombi nor C4d deposition correlated with LN
severity or outcome. Although the mechanisms of
thrombosis may be different, previous studies point to
complement activation and inflammation as common
mechanisms in LN- and aPL-associated vascular pathol-
ogy. In APS, a “two hits” theory has been proposed, in
which the presence of aPL would lead to thrombophilia
through endothelial cell, platelet, and monocyte
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activation ("first hit”), and a “second hit” related to
inflammation (that is, Toll-like receptors and comple-
ment activation, in response to microbial agents, might
synergize and result in clotting events [25]. Our data
link inflammatory infiltration and thrombosis in LN but
are less clear regarding the relation of complement acti-
vation and thrombosis.
Several studies point to the involvement of comple-
ment in the pathogenesis of APS. In animal models,
complement factors C3 and C5 are essential in aPL-
mediated pathology [15]. In these models, endothelial
cell activation and inflammatory cell infiltration around
blood vessels are observed in placental lesions, suggest-
ing that complications of pregnancy are primarily due to
inflammation [14]. In humans, a few studies also point
to complement activation in aPL-mediated thrombosis
[26-28]. Sera from patients with positive aPL enhance
complement fixation on platelets, which is associated
with arterial thrombosis [16]. Platelet-associated C4d
has been reported in 18% of patients with SLE, particu-
larly in those with aPL [29]. In addition, hypocomple-
mentemia and increased plasma levels of anaphylotoxins
C3a and C4a have been described in primary APS [26].
However, a direct correlation between increased levels
of anaphylotoxins and clinical thrombosis has not been
demonstrated [26,28].
Specifically in LN, immune-mediated vascular injury
may predispose to platelet accumulation and in situ com-
plement activation. Intense glomerular C4d deposition has
been previously found associated with renal microthrombi
in LN patients with or without aPL [15,28]. However,
because both processes may be associated with prolifera-
tive LN and higher activity indexes, this may be an indirect
association [26]. We have specifically analyzed patients
with proliferative LN and considered macrophage infiltra-
tion as an additional marker of inflammatory activity. Our
data do not demonstrate a direct relation between C4d
deposition and microthrombosis. Instead, C4d deposition
correlated with the intensity of macrophagic infiltration,
which in turn was associated with microthrombosis.
Deposition of C4d in peritubular capillaries reflected SLE
activity, consistent with previous reports [30,31]. Neither
C4d nor microthrombi were directly related to the severity
or outcome of LN.
Table 2 Clinical and laboratory associations of CD61-positive microthrombi, CD68-positive macrophage infiltration,
and C4d deposition
CD61 microthrombi CD68+ infiltration C4d deposition
+ - Glomerular Extraglomerular Glomerular Extraglomerular
SLEDAI 20.5 ± 6.9 20.3 ± 6.6 r = 0.5a r = 0.3a r = -0.1 r = 0.4a
aPL + 69% 33% 1.9 ± 1.9 1 ± 1.3 2.6 ± 2.9 0.9 ± 1.4
- 31% 67% 2.1 ± 3.1 0.4 ± 0.6 2.9 ± 4.7 1 ± 1.2
anti-dsDNA + 91% 74% 2.8 ± 3.2a 0.8 ± 1 2.4 ± 2.9 1.2 ± 1.4a
- 9% 26% 0.6 ± 0.7 0.5 ± 0.8 3.8 ± 6 0.5 ± 0.5
Low complement + 94% 87% 2.6 ± 3.1a 0.7 ± 1 2.4 ± 2.9 1.1 ± 1.4
- 6% 13% 0.5 ± 0.5 0.9 ± 0.9 5.4 ± 8 0.8 ± 0.5
24-hour proteinuria (g) 3.2 ± 3.1 3.6 ± 3.6 r = 0.4a r = 0.4a r = 0.1 r = 0.3a
Hematuria + 88% 84% 2.7 ± 3.2a 0.8 ± 0.9 2.7 ± 3.9 1.1 ± 1.4
- 12% 16% 0.6 ± 0.7 0.6 ± 1.4 2.9 ± 2.9 0.5 ± 0.6
Leukocyturia + 76.50% 84% 2.7 ± 3.2a 0.7 ± 0.9 2.7 ± 3.6 1.1 ± 1.4
- 23.50% 16% 1.3 ± 1.5 0.7 ± 1.2 2.8 ± 4.5 0.8 ± 1
Cellular casts + 62% 68% 3.1 ± 3.5a 0.8 ± 0.8 3.1 ± 4.2 1.1 ± 1.2
- 38% 32% 1.1 ± 1.3 0.7 ± 1.3 2.1 ± 2.7 0.9 ± 1.6
Creatinine clearance 97.9 ± 50.2 84.3 ± 35.6 r = -0.01 r = -0.2 r = 0.1 r = - 0.1
Response to treatment + 81% 95% 3.1 ± 3.5 0.8 ± 0.9 2.9 ± 4.2 1.2 ± 1.5
- 19% 5% 2.2 ± 1.4 1.3 ± 1.7 1.9 ± 1.5 0.9 ± 0.4
Mean time to response 25.1 ± 27.9 8.8 ± 10.8 r = -0.15 r = -0.26 r = -0.17 r = -0.05
LN relapse + 33% 45% 2.8 ± 3.3 0.6 ± 0.7 1.9 ± 2.9 1.1 ± 1.1
- 67% 55% 3.4 ± 4.4 0.7 ± 0.8 2.9 ± 3.5 1.4 ± 1.9
Renal failure at 1 year + 17.40% 15% 3.2 ± 3.6 0.8 ± 0.9 2.9 ± 4.2 1.3 ± 1.6
- 82.60% 85% 1.9 ± 2.1 1.5 ± 1.6 1.3 ± 1.7 1.2 ± 0.7
Renal failure at last visit + 20.80% 30% 3.3 ± 3.7 0.9 ± 1 3 ± 4.4 1.3 ± 1.6
- 79.20% 70% 2.1 ± 1.9 1 ± 1.4 1.5 ± 1.7 1 ± 0.7
aP < 0.05.
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The detection of CD61 intravascular platelets with
IHC is far more sensitive to acute microthrombi in
patients with LN compared with routine histologic
methods. Thrombi detected with regular histology might
have a different impact on renal outcomes but are rarely
observed. Clinical observations support that TMA in
APS or SLE nephritis has an important impact on renal
function and requires specific therapy. However, TMA
may occur independent of SLE nephritis, and its preva-
lence associated with LN is very low. Only two cases
had microthrombi detected by histology in our series,
precluding analyses of the clinical and subclinical
(immunohistochemical) correlations in LN. Our data do
not support any difference in renal manifestations and
outcomes at 6 and 12 months, and further follow-up
after therapy in patients with IHC detected CD61-posi-
tive microthrombi. The retrospective design of our
study limits the interpretation of results regarding clini-
cal correlations and prognosis. Microthrombi detected
with IHC may have a lower impact on renal function
and outcome than do larger histologic microthrombi.
Longitudinal prospective studies, including patients with
LN and repeated biopsies after induction treatment, will
help us to better define the real significance of this kind
of histologic and IHC lesion.
Macrophagic infiltration was the best marker of renal
impairment at kidney biopsy, consistent with previous stu-
dies [32]. Glomerular and interstitial macrophage infiltra-
tion is a feature of the more aggressive forms of LN and
the individual variable that best correlates with clinical
parameters, including SLE activity and renal manifesta-
tions. We found a correlation with activity measures,
including the level of proteinuria and active sediment, but
not with renal function at biopsy or follow-up. A previous
study showed that the persistence of glomerular and extra-
glomerular macrophagic infiltrates after therapy correlates
with long-term renal-function outcomes (doubling of
serum creatinine and end-stage renal disease) [32]. How-
ever, neither these nor our data demonstrates predictive
value for the degree of macrophage infiltration at first
biopsy and renal-function outcomes.
Conclusions
In summary, our results show a relation between renal
microthrombi and local inflammatory cells infiltration in
patients with LN. Renal macrophagic infiltration was the
best marker of SLE and renal clinical activity, whereas
microthrombi or C4d deposition did not have a direct
correlate with severity or prognosis in LN.
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